Drugs / albumin interferon alfa 2b
albumin interferon alfa 2b
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 3 | NCT00402428 | Dec 2006 → Feb 2009 | chronic hepatitis C virus infection | Human Genome Sciences Inc. | Completed | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | albumin interferon alfa 2b | “albumin interferon alfa 2b (alb-IFN)in combination with ribavirin” NCT00402428 ↗ |
| Known as | alb-IFN | “albinterferon alfa-2b (albIFN), a novel, long-acting, genetic fusion polypeptide of albumin and IFNα-2b.” PMID 20600013 ↗ Jun 20101“albumin interferon alfa 2b (alb-IFN)in combination with ribavirin” NCT00402428 ↗ |
| Known as | albinterferon alfa-2b | “Albinterferon Alfa-2b was not inferior to pegylated interferon-α in a randomized trial of patients with chronic hepatitis C virus genotype 1.” PMID 20600013 ↗ Jun 2010 |
| Modality | Protein / enzyme biologic | “a novel, long-acting, genetic fusion polypeptide of albumin and IFNα-2b.” PMID 20600013 ↗ Jun 2010 |
| Route | Subcutaneous | “albIFN 900 or 1200 μg every 2 weeks administered subcutaneously” PMID 20600013 ↗ Jun 2010 |